Cleveland Clinic to Lead First Head-to-Head Comparison of the Two Most Potent Statins
Posted on: Tuesday, 15 January 2008, 09:00 CST
CLEVELAND, Jan. 15 /PRNewswire/ -- Cleveland Clinic researchers will coordinate the first head-to-head comparison of the two most powerful statin medications. The trial intends to begin enrollment as early as next week. Statins are the world's most commonly prescribed drugs and widely used to treat patients with elevated cholesterol levels.
The two drugs, atorvastatin (Lipitor) and rosuvastatin (Crestor), lower LDL ("bad") cholesterol and raise HDL ("good") cholesterol. But which drug is best for patients with heart disease? This study will seek to answer this important scientific question by measuring the rate of regression of coronary disease using intravascular ultrasound (IVUS), a technique that directly measures the amount of plaque in the coronary arteries.
The SATURN study (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN) will compare the ability of these two statins to stop the progression of atherosclerosis, the main cause of cardiovascular disease, over a two year treatment period.
SATURN, a multicenter, double-blind Phase IIIb trial, will use IVUS imaging to study approximately 1,300 patients at 150 hospitals in 20 countries worldwide. The trial is expected to be completed in 2011. Cleveland Clinic cardiologist Stephen J. Nicholls, M.D., PhD., will lead the trial.
Cleveland Clinic researchers have conducted two previous studies with IVUS looking at statins and the rate of atherosclerosis regression. Researchers have found a significant benefit with statins by intensively lowering LDL- cholesterol and the inflammatory marker C-reactive protein (CRP) and by raising levels of HDL cholesterol. SATURN aims to determine if differences in the ability of the different statins to lower LDL and raise HDL can promote regression (reduction in the amount of plaque in the coronary arteries).
About Cleveland Clinic
Cleveland Clinic, located in Cleveland, Ohio, is a not-for-profit multispecialty academic medical center that integrates clinical and hospital care with research and education. Cleveland Clinic was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. U.S. News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual "America's Best Hospitals" survey. Approximately 1,800 full-time salaried physicians and researchers at Cleveland Clinic and Cleveland Clinic Florida represent more than 100 medical specialties and subspecialties. In 2006, there were 3.1 million outpatient visits to Cleveland Clinic. Patients came for treatment from every state and from more than 80 countries. There were more than 53,000 hospital admissions to Cleveland Clinic in 2006. Cleveland Clinic's Web site address is http://www.clevelandclinic.org/ .
Cleveland Clinic
CONTACT: Erinne Dyer, +1-216-444-8168, dyere@ccf.org, or Natalie Guzzo,+1-216-444-5703, guzzon@ccf.org, both of Cleveland Clinic
Web site: http://www.clevelandclinic.org/
Source: PRNewswire
Related Articles
- Cleveland Clinic Study Suggests Failure of HDL-Raising Drug Torcetrapib is Likely Compound Specific
- Cleveland Clinic Press Releases Consumer Health Book About Treating Headache Pain
- Cleveland Clinic Press Releases Journal-Writing Book 'Write for Life: Healing Body, Mind, and Spirit Through Journal Writing' By Sheppard B. Kominars, Ph.D.
- Researchers at Cleveland Clinic Identify Site of 'Dysfunction' in HDL, Carrier of Good Cholesterol
- Abbott Enrolls First Patient in World's First Clinical Trial Designed to Study Drug Eluting Stent Treatment in Women
- For the 13th Year in a Row, Cleveland Clinic Heart Center is Ranked No. 1 in U.S. News & World Report 'America's Best Hospital' Survey
- Cleveland Clinic Study Demonstrates TASER X26 Does Not Affect Short-Term Function of Implantable Pacemakers and Defibrillators
- Biopure Completes Patient Enrollment in European Phase 2 Clinical Trial of Hemopure(R) in Coronary Angioplasty Patients
- Benefits Found in High Doses of Statins; Reducing Cholesterol in Heart Patients Lowers Risk of Heart Attacks, Strokes, 5-Year Study Shows
- 'Heart Attack Gene' Discovered at Cleveland Clinic Exists in 1-2% of U.S. Heart Attack, Coronary Artery Disease Patients
User Comments (0)

RSS Feeds